Abbott to acquire vascular disease specialists for $890M

Michael Walter | February 09, 2023 | Cardiovascular Business | Interventional Cardiology

Abbott has entered into a definitive agreement to acquire Cardiovascular Systems Inc. (CSI), a Minnesota-based healthcare technology company focused on treating peripheral artery disease (PAD) and coronary artery disease (CAD). The deal is worth approximately $890 million, and CSI’s stock price was up significantly after the announcement.

The acquisition will clearly help Abbott expand its cardiovascular portfolio. CSI is known for its atherectomy devices, including the Diamondback 360 Coronary Orbital Atherectomy System for treating CAD and Diamondback 360 Peripheral Orbital Atherectomy System for treating PAD.

“The acquisition of CSI will add new, complementary technologies to Abbott's leading vascular device offerings,” Lisa Earnhardt, Abbott’s executive vice president of medical devices, said in a prepared statement. “CSI has a talented and experienced team and a leading atherectomy system that will allow Abbott to provide physicians more tools to help patients live fuller lives.”

The CSI Diamondback 360 atherectomy system grinding through a calcified coronary lesion.

One of CSI's Diamondback 360 atherectomy devices grinding through a calcified coronary lesion. Image courtesy of CSI.

“We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease,” added Scott Ward, CSI's chairman, president and chief executive officer. “We believe combining with Abbott delivers value to our patients, physician customers, employees and stockholders while continuing our work to save limbs and save lives every day.”

Once the deal has been finalized, CSI stockholders will receive $20 for each common share. The transaction has already been approved by both the Abbott Board of Directors and CSI Board of Directors.

In September 2021, Abbott acquired another vascular device company, Walk Vascular, though the financial details of that deal were not made public.

Medtronic urges shareholders to reject below-market offer from investment firm

Increased use of CCTA improves CAD outcomes without raising costs

Shockwave Medical to acquire medical device company for $100M

Canon Medical Systems announces new partnership focused on enterprise imaging and hemodynamics

Abbott acquires vascular device company, will now offer its peripheral thrombectomy solutions

Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.